US demand has a ceiling. Here's how to expand a peptide brand's Google and Meta Ads internationally, market by market, without a compliance surprise.
Every peptide brand running Google and Meta ads in the US eventually hits the same ceiling: a finite pool of US search demand, a single regulatory environment's worth of policy risk, and an ad account whose entire revenue depends on one country's platform enforcement staying consistent. International expansion solves all three problems at once — it's new addressable demand, and it's genuine risk diversification, since a policy shift, an account issue, or a regulatory crackdown in one market doesn't zero out the others.
This is a market-by-market playbook for taking a peptide or research-chemical brand's Google and Meta Ads into the UK, Europe, Australia and New Zealand, parts of Asia, and the Middle East — built from campaigns we've actually planned and run in these regions, not desk research assembled from regulatory summaries.
Google and Meta enforce their restricted health and pharmaceutical policies globally, with the same core standards everywhere the platforms operate. What changes market to market is the local advertising and consumer protection law layered on top — and in several of these markets, the local layer is stricter than the platform's baseline policy, meaning "compliant on Google's global policy" is a necessary but not sufficient condition for a given market. Treat every new market as "platform policy plus local law," not platform policy alone, and budget time for local compliance review before launch rather than after a complaint.
The UK's Advertising Standards Authority (ASA) and CAP Code govern health claims independently of platform policy, and MHRA regulation applies to anything that reads as a medicinal claim. UK audiences also respond well to research-and-testing-forward messaging — the same outcome-adjacent framing that keeps you compliant on Google performs well creatively here too, which makes the UK a relatively low-friction first international market for most US peptide brands, both regulatorily and linguistically.
The EU's Health Claims Regulation restricts what can be said about a substance's effect on the body far more tightly than US FTC guidance does, and Germany's Heilmittelwerbegesetz (HWG) adds an additional, strictly enforced layer specific to advertising health-related products — Germany is consistently the most conservative market we operate in on claims language, and campaigns there need a genuinely rewritten, not just translated, compliance framework. Spain and Italy sit closer to UK-level strictness in practice, with more workable latitude for research-use framing. Norway (EEA, not EU, but aligned on most advertising standards) is smaller in volume but has proven a receptive, low-competition market for research-focused peptide messaging, often overlooked by brands who default straight to the larger EU economies. Currency, VAT display requirements, and language localization all need to be handled per-market — a single translated landing page reused across four countries under-serves all four and reads as noticeably foreign to each audience.
The Therapeutic Goods Administration (TGA) in Australia has specific, actively enforced restrictions on advertising for products that could be construed as therapeutic goods, and the ACCC governs broader consumer protection and misleading-claims standards on top of that. This market rewards exactly the compliance discipline peptide brands should already be running in the US — clean, research-use framing translates directly, and English-language creative can often be adapted rather than rebuilt from scratch, making Australia and New Zealand one of the more efficient markets to enter once the UK is proven out.
Japan's PMDA (Pharmaceuticals and Medical Devices Agency) enforces some of the strictest advertising standards globally for anything adjacent to a therapeutic claim, and cultural expectations around trust signals and formality in advertising differ meaningfully from Western markets — this is not a market to enter with directly translated US creative, and campaigns need local review from someone who understands both the regulatory and cultural context, not just the language. Southeast Asia (Singapore, Malaysia, and neighboring markets) varies significantly by country in enforcement intensity, but generally rewards the same research-and-testing-forward, outcome-adjacent approach that works everywhere else, adapted for local payment methods and, in several markets, WhatsApp or messaging-app-driven customer service expectations that differ substantially from US or European norms.
UAE and Saudi Arabia both have active restrictions on supplement and pharmaceutical-adjacent advertising, with enforcement bodies (including the UAE's MOHAP) that review both claims and, in some cases, product registration status directly. This is the market where local legal review before launch matters most of any region covered here — the gap between "compliant on Google's global policy" and "compliant under local Middle East law" is widest here, and getting it wrong carries consequences beyond a simple ad disapproval.
South American markets vary considerably by country in both platform enforcement intensity and local regulatory maturity for this category, but consistently reward the same core discipline: research-use framing, third-party testing transparency, and localized (not just translated) landing pages that account for local payment preferences, which differ substantially from US card-first checkout norms. It's a market with meaningfully less peptide-specific ad competition than the US or UK, which can mean more efficient CPMs for brands willing to build out proper localization rather than treating it as an afterthought market.
Don't launch five markets simultaneously. The brands that expand successfully pick one adjacent market first — usually the UK or Australia for US brands, given language and regulatory similarity — prove the campaign architecture and compliance framework works there, then use that as the template for the next market rather than reinventing the compliance review process from scratch each time. Budget-wise, expect the first new market to take longer to reach efficiency than your home market did, purely because you're re-learning local search behavior and creative response with less historical data to work from, and build that lag into your expectations before you launch rather than treating slower early performance as a signal to pull back.
Keep campaigns geographically segmented rather than consolidated wherever budget allows — separate campaigns per country (or per closely-aligned region) let you manage compliance, bidding, and creative independently, and prevent a policy issue tied to one market's landing page variant from affecting delivery in markets where you're fully compliant. Google Ads and Meta both support this natively through campaign-level geo-targeting and localized ad sets, and the marginal setup cost is worth the isolation it buys you when something does go wrong in one specific market.
Most agencies serving peptide brands have only ever run US campaigns. Our team has planned and run paid media for peptide and adjacent brands in South America, the UK, Spain, Germany, Norway, and Italy across Europe, Australia and New Zealand, Japan and Southeast Asia across Asia, and the Middle East, alongside the US core market — which means when a client asks about expanding into a specific region, the answer comes from having actually managed the compliance review and campaign architecture there, not from a generic international-expansion framework assembled from public regulatory summaries.
The UK or Australia, for most brands — both share enough regulatory and linguistic similarity with the US that campaign architecture and creative can be adapted rather than rebuilt, letting you prove the international expansion model with lower setup cost before tackling markets like Germany or Japan that require more substantial local rework.
The core platform policy is global and consistent, but local law adds an additional compliance layer on top that varies significantly by country — in several markets covered here, particularly Germany and the Middle East, the local legal standard is stricter than the platform's baseline policy, so platform compliance alone isn't sufficient.
Separate, geographically segmented campaigns almost always perform better and carry less risk for this category — they let you manage compliance, bidding, and creative independently per market, and isolate any policy issue to the specific market's campaign rather than risking delivery everywhere.
Expect a meaningfully longer ramp than your home market, since you're rebuilding search behavior and creative-response data from a smaller base with less history. This is normal and shouldn't be read as a signal the market doesn't work — it typically resolves within the first 60-90 days as the account accumulates local data.
See how compliance-first campaign architecture performed for a cold-start peptide recovery brand.
Get a free 30-minute audit of your Google Ads or Meta Ads account. We’ll review compliance, structure, and growth opportunities — no strings attached.
Book a Free Audit